Clinical Trial Update: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. [Phase 3]

View source ↗

Summary

Phase III trial update evaluating durvalumab after curative-intent therapy in stage II-III non-small cell lung cancer; results were posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non- Small Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2024-06-25